



NDA 021923/S-23

**CBE SUPPLEMENT –  
ACKNOWLEDGEMENT/ SUPPLEMENT APPROVAL**

Bayer HealthCare Pharmaceuticals Inc.  
Attention: Kaitlyn Orland, Pharm.D., RPh  
Manager, Regulatory Affairs  
100 Bayer Blvd.  
P.O. Box 915  
Whippany, NJ 07981-0915

Dear Dr. Orland:<sup>1</sup>

We have received your supplemental new drug application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

**NDA NUMBER:** 021923  
**SUPPLEMENT NUMBER:** 23  
**PRODUCT NAME:** Nexavar (sorafenib tosylate) tablets  
**DATE OF SUBMISSION:** March 24, 2020  
**DATE OF RECEIPT:** March 24, 2020

This supplemental application, submitted as a “Changes Being Effected” supplement, proposes the following change: Revision to Postmarketing Experience subsection (6.2) to include Blood and lymphatic disorders: Thrombotic microangiopathy (TMA).

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling, with minor editorial revisions listed below and reflected in the enclosed labeling.

- Date at the end of the Highlights of Prescribing Information updated to “Revised 4/2020”.

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>2</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with this CBE-0 labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>3</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

---

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>3</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions you may contact Felicia Diggs, Safety Regulatory Project Manager, at (240) 402-4932 or via email at [Felicia.diggs@fda.hhs.gov](mailto:Felicia.diggs@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Abhilasha Nair, M.D.  
Associate Director for Safety (acting)  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

### ENCLOSURE:

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ABHILASHA NAIR  
04/02/2020 03:27:13 PM